These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

758 related articles for article (PubMed ID: 30995089)

  • 1. Radioligand Therapy With
    Yadav MP; Ballal S; Sahoo RK; Dwivedi SN; Bal C
    AJR Am J Roentgenol; 2019 Aug; 213(2):275-285. PubMed ID: 30995089
    [No Abstract]   [Full Text] [Related]  

  • 2. Third-line treatment and
    von Eyben FE; Roviello G; Kiljunen T; Uprimny C; Virgolini I; Kairemo K; Joensuu T
    Eur J Nucl Med Mol Imaging; 2018 Mar; 45(3):496-508. PubMed ID: 29247284
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment Outcome, Toxicity, and Predictive Factors for Radioligand Therapy with
    Heck MM; Tauber R; Schwaiger S; Retz M; D'Alessandria C; Maurer T; Gafita A; Wester HJ; Gschwend JE; Weber WA; Schwaiger M; Knorr K; Eiber M
    Eur Urol; 2019 Jun; 75(6):920-926. PubMed ID: 30473431
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 177 Lu-PSMA-617 radioligand therapy of metastatic castration-resistant prostate cancer: Initial 254-patient results from a prospective registry (REALITY Study).
    Khreish F; Ghazal Z; Marlowe RJ; Rosar F; Sabet A; Maus S; Linxweiler J; Bartholomä M; Ezziddin S
    Eur J Nucl Med Mol Imaging; 2022 Feb; 49(3):1075-1085. PubMed ID: 34494131
    [TBL] [Abstract][Full Text] [Related]  

  • 5.
    Cao J; Chen Y; Hu M; Zhang W
    Ann Nucl Med; 2021 Aug; 35(8):861-870. PubMed ID: 34176105
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of novel PSMA-targeting [
    Li L; Wang J; Wang G; Wang R; Jin W; Zang J; Sui H; Jia C; Jiang Y; Hong H; Zhu L; Alexoff D; Ploessl K; Kung HF; Zhu Z
    Eur J Nucl Med Mol Imaging; 2024 Jul; 51(9):2794-2805. PubMed ID: 38658392
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Explorative analysis of a score predicting the therapy response of patients with metastatic, castration resistant prostate cancer undergoing radioligand therapy with
    Huang K; Schatka I; Rogasch JMM; Lindquist RL; De Santis M; Erber B; Radojewski P; Brenner W; Amthauer H
    Ann Nucl Med; 2021 Mar; 35(3):314-320. PubMed ID: 33351172
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Lutetium-177-PSMA radioligand therapy : Consensus within the framework of GKV-funded care between the university hospitals in Aachen, Bonn, Düsseldorf, Essen, and Cologne and the MDK Nordrhein].
    Ahmadzadehfar H; Albers P; Bockisch A; Boegemann M; Böhme C; Burchert W; Dietlein M; Drzezga A; Fabry U; Feldmann G; Heidenreich A; Heinzel A; Herrmann K; Heyll A; Höhling C; Kreuzer C; Laufer D; Mengel R; Mottaghy FM; Müller HW; Müller SC; Ost E; Rahbar K; Reifenhäuser W; Schäfers M; Schlenkhoff C; Schmidt M; Schmidt-Wolf I; Wildenhain C; Zimmer B; Essler M
    Urologe A; 2018 Jun; 57(6):709-713. PubMed ID: 29671080
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adoption of Lutetium-
    Flegar L; Thoduka SG; Librizzi D; Luster M; Zacharis A; Heers H; Eisenmenger N; Ahmadzadehfar H; Eiber M; Weber W; Groeben C; Huber J
    Eur J Nucl Med Mol Imaging; 2023 Jun; 50(7):2188-2195. PubMed ID: 36826478
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [
    Satapathy S; Sahoo RK; Bal C
    J Nucl Med; 2023 Aug; 64(8):1266-1271. PubMed ID: 37169534
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The real-world outcomes of Lutetium-177 PSMA-617 radioligand therapy in metastatic castration-resistant prostate cancer: Turkish Oncology Group multicenter study.
    Almuradova E; Seyyar M; Arak H; Tamer F; Kefeli U; Koca S; Sen E; Telli TA; Karatas F; Gokmen I; Turhal NS; Sakalar T; Ayhan M; Ekinci F; Hafizoglu E; Kahraman S; Kesen O; Unal C; Alan O; Celik S; Yekeduz E; Omur O; Gokmen E
    Int J Cancer; 2024 Feb; 154(4):692-700. PubMed ID: 37818966
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Should Lutetium-prostate specific membrane antigen radioligand therapy for metastatic prostate cancer be used earlier in men with lymph node only metastatic prostate cancer?
    Yaxley WJ; McBean R; Wong D; Grimes D; Vasey P; Frydenberg M; Yaxley JW
    Investig Clin Urol; 2021 Nov; 62(6):650-657. PubMed ID: 34729965
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and Efficacy of [
    Tauber R; Knorr K; Retz M; Rauscher I; Grigorascu S; Hansen K; D'Alessandria C; Wester HJ; Gschwend J; Weber W; Eiber M; Langbein T
    J Nucl Med; 2023 Aug; 64(8):1244-1251. PubMed ID: 37321824
    [No Abstract]   [Full Text] [Related]  

  • 14. Real-world Outcomes and Predictive Biomarkers for
    Kafka M; Horninger A; di Santo G; Virgolini I; Neuwirt H; Unterrainer LM; Kunte SC; Deiss E; Paffenholz P; Heidenreich A; Rasul S; Einspieler H; Shariat SF; Rajwa P; Dozauer R; Tsaur I; Medlock E; Rölz N; Rausch S; la Fougère C; Trautwein N; Roesch MC; Merseburger AS; Zattoni F; Sepulcri M; Ladurner M; Bektic J; Gandaglia G; Horninger W; Heidegger I
    Eur Urol Oncol; 2024 Jun; 7(3):421-429. PubMed ID: 37604763
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Systematic Review and Meta-analysis of the Effectiveness and Toxicities of Lutetium-177-labeled Prostate-specific Membrane Antigen-targeted Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer.
    Sadaghiani MS; Sheikhbahaei S; Werner RA; Pienta KJ; Pomper MG; Solnes LB; Gorin MA; Wang NY; Rowe SP
    Eur Urol; 2021 Jul; 80(1):82-94. PubMed ID: 33840558
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Visceral Metastases as Predictors of Response and Survival Outcomes in Patients of Castration-Resistant Prostate Cancer Treated With 177Lu-Labeled Prostate-Specific Membrane Antigen Radioligand Therapy: A Systematic Review and Meta-analysis.
    Satapathy S; Mittal BR; Sood A
    Clin Nucl Med; 2020 Dec; 45(12):935-942. PubMed ID: 32956129
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activity and Adverse Events of Actinium-225-PSMA-617 in Advanced Metastatic Castration-resistant Prostate Cancer After Failure of Lutetium-177-PSMA.
    Feuerecker B; Tauber R; Knorr K; Heck M; Beheshti A; Seidl C; Bruchertseifer F; Pickhard A; Gafita A; Kratochwil C; Retz M; Gschwend JE; Weber WA; D'Alessandria C; Morgenstern A; Eiber M
    Eur Urol; 2021 Mar; 79(3):343-350. PubMed ID: 33293081
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    Sahin E; Elboga U; Cimen U; Okuyan M; Cayirli YB
    Curr Radiopharm; 2024; 17(4):356-363. PubMed ID: 38571351
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Response and outcome of liver metastases in patients with metastatic castration-resistant prostate cancer (mCRPC) undergoing
    Khreish F; Kochems N; Rosar F; Sabet A; Ries M; Maus S; Saar M; Bartholomä M; Ezziddin S
    Eur J Nucl Med Mol Imaging; 2021 Jan; 48(1):103-112. PubMed ID: 32378019
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Extended therapy with [
    Mader N; Nguyen Ngoc C; Kirkgöze B; Baumgarten J; Groener D; Klimek K; Happel C; Tselis N; Chun FKH; Grünwald F; Sabet A
    Eur J Nucl Med Mol Imaging; 2023 May; 50(6):1811-1821. PubMed ID: 36702927
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 38.